S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.21
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.51
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
FTH · Faeth Therapeutics, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Faeth Therapeutics, Inc (FTH)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$20.50
-0.26
(-1.25%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$20.50
$20.32
$21.33
52-WEEK RANGE
$20.50
$13.43
$42.14
What's happening
- FTH is down 1.25% today, trading at $20.50. — Live quote
- Volume today (6,533) is well below its 3-month average of 317,340. (Finnhub fundamentals)
- Reports earnings on 2026-11-10, 19 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-2.84 actual vs. $-3.08 estimated (+7.7%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 7
Buy 10
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (18 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
FTH
+43.08%
vs S&P 500
+40.59%
3-MONTH RETURN
FTH
-26.72%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-2.84
Est. $-3.08
BEAT +7.7%
2026-04-26 (Q1 2026)
$-28.79
Est. $-0.63
MISS -4497.6%
2026-01-26 (Q4 2025)
$-3.74
Est. $-4.86
BEAT +23.0%
2025-10-26 (Q3 2025)
$-3.62
Est. $-4.15
BEAT +12.8%
Valuation Measures & Ratios
Enterprise Value4$510.3M
Forward P/E5—
PEG Ratio6-0.00
Price / Sales (TTM1)—
Price / Book73.59
EV4 / Revenue—
EV4 / EBITDA—
Profit Margin—
Operating Margin—
Return on Equity (ROE8)-189.59%
Return on Assets (ROA9)-175.68%
Avg Volume (3M)317,340
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $139.6M | $41.8M | $11.7M | $10.5M | $10.2M |
| P/E | -0.71 | -0.22 | -0.49 | -0.40 | -0.35 |
| Price/Book | 0.81 | -0.30 | 0.51 | 0.39 | 0.32 |
| EV/EBITDA | -0.57 | 0.59 | -0.04 | — | — |
| ROE | -113.18% | 135.92% | -102.67% | -95.90% | -91.45% |
| ROA | -103.40% | -90.86% | -85.62% | -82.42% | -76.43% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short2,067,445
Change from Prior Settlement+56.76%
% of Float—
Days to Cover (Short Ratio)3.63
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
Not enough positive evidence under the current rules.
Potential concerns
- Latest SEC filing is Form 8-K, filed 2026-09-17; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on FTH
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Operating income | -$18.4M | -$170.6M | -$4.9M | -$5.2M | -$7.3M | -$7.8M | -$7.8M | -$8.7M |
| Net income | -$16.0M | -$170.2M | -$4.6M | -$4.9M | -$6.9M | -$7.3M | -$7.1M | -$8.0M |
| EPS (diluted) | $-2.84 | $-131.45 | $-3.62 | $-3.91 | $-5.45 | $-5.77 | $-5.69 | $-0.32 |
| EPS (basic) | $-2.84 | $-131.45 | $-3.62 | $-3.91 | $-5.45 | $-5.77 | $-5.69 | $-0.32 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $189.3M | $205.4M | $22.9M | $27.6M | $31.8M | $38.3M | $45.4M | $53.3M |
| Total liabilities | $9.6M | $14.2M | $4.3M | $4.6M | $4.5M | $6.3M | $7.0M | $7.5M |
| Stockholders' equity | $173.0M | -$137.3M | $18.6M | $23.0M | $27.3M | $32.0M | $38.4M | $45.8M |
| Total current assets | $188.7M | $204.2M | $21.5M | $25.8M | $29.6M | $35.7M | $41.9M | $48.1M |
| Total current liabilities | $9.6M | $14.2M | $4.3M | $4.4M | $3.9M | $5.2M | $5.4M | $5.4M |
| Cash & equivalents | $26.9M | $152.3M | $8.7M | $10.6M | $12.6M | $9.9M | $10.0M | $19.1M |
| Marketable securities (current) | — | — | — | — | — | — | — | — |
| Other current assets | $858.0K | $465.0K | $92.0K | $248.0K | $116.0K | $440.0K | $120.0K | $81.0K |
| Property, plant & equipment | $44.0K | $69.0K | $82.0K | $112.0K | $143.0K | $159.0K | $417.0K | $899.0K |
| Goodwill | $0 | $0 | — | — | — | — | — | — |
| Other non-current assets | $80.0K | $167.0K | $18.0K | $18.0K | $24.0K | $24.0K | $48.0K | $87.0K |
| Accounts payable | $2.1M | $3.4M | $689.0K | $306.0K | $351.0K | $361.0K | $244.0K | — |
| Accrued liabilities | $5.3M | $5.4M | $715.0K | $1.0M | $704.0K | $1.9M | $847.0K | — |
| Other current liabilities | $175.0K | $136.0K | $77.0K | $80.0K | $76.0K | $75.0K | $126.0K | — |
| Long-term debt | — | — | — | — | — | — | — | — |
| Other non-current liabilities | $1.0K | $1.0K | $0 | — | — | — | — | — |
| Common stock & paid-in capital | $2.0K | $0 | $0 | $0 | $0 | $3.0K | $0 | $3.0K |
| Retained earnings | -$469.4M | -$453.4M | -$283.1M | -$278.4M | -$273.9M | -$268.9M | -$262.1M | -$254.3M |
| Accumulated other comprehensive income (loss) | -$63.0K | -$24.0K | $1.0K | -$3.0K | -$11.0K | -$6.0K | -$13.0K | $14.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$15.7M | -$10.7M | -$3.9M | -$3.6M | -$5.9M | -$7.1M | -$5.8M | -$5.5M |
| Investing cash flow | -$108.1M | -$31.4M | $2.1M | $1.7M | $8.8M | $7.2M | -$3.2M | $12.9M |
| Financing cash flow | -$1.7M | $185.8M | -$111.0K | -$152.0K | -$168.0K | -$214.0K | -$194.0K | -$204.0K |
| Free cash flow | -$15.7M | -$10.7M | -$3.9M | -$3.6M | -$5.9M | -$7.1M | -$5.8M | -$5.5M |
| Capital expenditures | $0 | $6.0K | $0 | $0 | $16.0K | $0 | $0 | $0 |
| Depreciation & amortization | $25.0K | $29.0K | $30.0K | $30.0K | $32.0K | $30.0K | $139.0K | $140.0K |
| Share-based compensation | $4.5M | $12.9M | $295.0K | $254.0K | $264.0K | $461.0K | $391.0K | $733.0K |
| Deferred income taxes | — | — | -$2.6M | — | — | — | -$7.2M | — |
| Share repurchases | — | — | — | — | — | — | — | — |
| Tax withholding on stock comp | $0 | $0 | $0 | $0 | $0 | $3.0K | $0 | $0 |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating income | -$22.3M | -$32.6M | -$37.1M | -$50.2M | -$37.5M |
| Net income | -$21.1M | -$30.2M | -$34.1M | -$48.6M | -$36.8M |
| EPS (diluted) | $-16.72 | $-24.01 | $-1.22 | $-1.58 | $-1.33 |
| EPS (basic) | $-16.72 | $-24.01 | $-1.22 | $-1.58 | $-1.33 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $22.9M | $45.4M | $74.4M | $118.4M | $153.2M |
| Total liabilities | $4.3M | $7.0M | $9.5M | $15.0M | $6.7M |
| Stockholders' equity | $18.6M | $38.4M | $64.9M | $103.4M | $146.5M |
| Total current assets | $21.5M | $41.9M | $67.2M | $108.6M | $148.5M |
| Total current liabilities | $4.3M | $5.4M | $5.6M | $9.1M | $4.9M |
| Cash & equivalents | $8.7M | $10.0M | $13.0M | $17.8M | $7.2M |
| Marketable securities (current) | — | — | — | — | $140.5M |
| Other current assets | $92.0K | $120.0K | $325.0K | $344.0K | $374.0K |
| Property, plant & equipment | $82.0K | $417.0K | $1.2M | $2.0M | $4.6M |
| Other non-current assets | $18.0K | $48.0K | $86.0K | $63.0K | $39.0K |
| Accounts payable | $689.0K | $244.0K | $573.0K | — | — |
| Accrued liabilities | $715.0K | $847.0K | $900.0K | — | — |
| Other current liabilities | $77.0K | $126.0K | $221.0K | — | — |
| Long-term debt | — | — | — | — | — |
| Other non-current liabilities | — | — | $67.0K | — | $149.0K |
| Common stock & paid-in capital | $0 | $0 | $3.0K | $3.0K | $3.0K |
| Retained earnings | -$283.1M | -$262.1M | -$231.9M | -$197.8M | -$149.2M |
| Accumulated other comprehensive income (loss) | $1.0K | -$13.0K | -$209.0K | -$1.0M | -$333.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$20.5M | -$24.7M | -$32.0M | -$39.0M | -$30.3M |
| Investing cash flow | $19.8M | $22.4M | $38.4M | $49.9M | -$143.1M |
| Financing cash flow | -$645.0K | -$787.0K | -$11.2M | -$287.0K | $163.9M |
| Free cash flow | -$20.5M | -$24.8M | -$32.2M | -$39.3M | -$32.3M |
| Capital expenditures | $16.0K | $146.0K | $180.0K | $321.0K | $2.0M |
| Depreciation & amortization | $122.0K | $551.0K | $571.0K | $614.0K | $685.0K |
| Share-based compensation | $1.3M | $3.1M | $4.5M | $5.8M | $5.7M |
| Deferred income taxes | -$2.6M | -$7.2M | -$9.9M | -$8.0M | -$8.3M |
| Share repurchases | — | — | $10.4M | — | — |
| Tax withholding on stock comp | $3.0K | $10.0K | $76.0K | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding FTH as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-12-04 to 2026-07-01
Recent transactions
- Insiders have net sold 506 shares over the last 182 days, across 23 purchases and 4 sales.
- Most recent: STEPHENSON BRIAN C (Chief Financial Officer) — Open market purchase of 4,400 shares on 2026-07-01.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)49,494 sh(23 txns)
Sales (open market)50,000 sh(4 txns)
Net Shares-506
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| STEPHENSON BRIAN C | Chief Financial Officer | Open market purchase | 2026-07-01 | 4,400 |
| Parikh Anand Kiran | President and CEO | Open market purchase | 2026-06-22 | 2,806 |
| Hahn Stephen M. | Reporting person | Derivative conversion | 2026-06-15 | 44,763 |
| Cambrian BioPharma Inc | Reporting person | Open market sale | 2026-06-01 | 24,524 |
| Peyer James | Reporting person | Open market sale | 2026-06-01 | 24,524 |
| MILLENNIUM MANAGEMENT LLC | 10% owner | Open market purchase | 2026-04-07 | 1,108 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-07-01 | STEPHENSON BRIAN C | Chief Financial Officer | Open market purchase | 4,400 | $23.40 |
| 2026-07-01 | STEPHENSON BRIAN C | Chief Financial Officer | Open market purchase | 600 | $24.22 |
| 2026-06-30 | STEPHENSON BRIAN C | Chief Financial Officer | Open market purchase | 1,910 | $22.95 |
| 2026-06-30 | STEPHENSON BRIAN C | Chief Financial Officer | Open market purchase | 1,638 | $23.88 |
| 2026-06-30 | STEPHENSON BRIAN C | Chief Financial Officer | Open market purchase | 4,255 | $24.98 |
| 2026-06-29 | STEPHENSON BRIAN C | Chief Financial Officer | Open market purchase | 831 | $23.34 |
| 2026-06-26 | STEPHENSON BRIAN C | Chief Financial Officer | Open market purchase | 580 | $23.61 |
| 2026-06-26 | STEPHENSON BRIAN C | Chief Financial Officer | Open market purchase | 4,212 | $24.90 |
| 2026-06-26 | STEPHENSON BRIAN C | Chief Financial Officer | Open market purchase | 1,358 | $25.55 |
| 2026-06-26 | STEPHENSON BRIAN C | Chief Financial Officer | Open market purchase | 100 | $26.39 |
| 2026-06-24 | STEPHENSON BRIAN C | Chief Financial Officer | Open market purchase | 2,891 | $25.22 |
| 2026-06-24 | STEPHENSON BRIAN C | Chief Financial Officer | Open market purchase | 3,000 | $25.98 |
| 2026-06-24 | STEPHENSON BRIAN C | Chief Financial Officer | Open market purchase | 3,400 | $26.98 |
| 2026-06-24 | STEPHENSON BRIAN C | Chief Financial Officer | Open market purchase | 100 | $27.77 |
| 2026-06-23 | STEPHENSON BRIAN C | Chief Financial Officer | Open market purchase | 6,836 | $24.12 |
| 2026-06-23 | STEPHENSON BRIAN C | Chief Financial Officer | Open market purchase | 1,969 | $24.84 |
| 2026-06-23 | STEPHENSON BRIAN C | Chief Financial Officer | Open market purchase | 425 | $25.91 |
| 2026-06-22 | STEPHENSON BRIAN C | Chief Financial Officer | Open market purchase | 1,797 | $20.23 |
| 2026-06-22 | STEPHENSON BRIAN C | Chief Financial Officer | Open market purchase | 1,118 | $20.82 |
| 2026-06-22 | STEPHENSON BRIAN C | Chief Financial Officer | Open market purchase | 1,583 | $22.40 |
| 2026-06-22 | STEPHENSON BRIAN C | Chief Financial Officer | Open market purchase | 3,329 | $23.28 |
| 2026-06-22 | STEPHENSON BRIAN C | Chief Financial Officer | Open market purchase | 356 | $23.95 |
| 2026-06-22 | Parikh Anand Kiran | President and CEO | Open market purchase | 2,806 | $19.76 |
| 2026-06-22 | Parikh Anand Kiran | President and CEO | Option exercise | 45,252 | $1.16 |
| 2026-06-22 | Parikh Anand Kiran | President and CEO | Option exercise | 8,213 | $1.16 |
| 2026-06-15 | Parikh Anand Kiran | President and CEO | Derivative conversion | 761,428 | — |
| 2026-06-15 | Hahn Stephen M. | Reporting person | Derivative conversion | 44,763 | — |
| 2026-06-01 | Cambrian BioPharma Inc | Reporting person | Open market sale | 24,524 | $20.00 |
| 2026-06-01 | Cambrian BioPharma Inc | Reporting person | Open market sale | 476 | $21.14 |
| 2026-06-01 | Peyer James | Reporting person | Open market sale | 24,524 | $20.00 |
| 2026-06-01 | Peyer James | Reporting person | Open market sale | 476 | $21.14 |
| 2026-04-07 | MILLENNIUM MANAGEMENT LLC | 10% owner | Open market purchase | 1,108 | $33.38 |
| 2026-04-07 | MILLENNIUM MANAGEMENT LLC | 10% owner | Open market sale | 2,115 | $28.94 |
| 2026-04-07 | MILLENNIUM MANAGEMENT LLC | 10% owner | Open market sale | 205 | $29.71 |
| 2026-04-07 | MILLENNIUM MANAGEMENT LLC | 10% owner | Open market sale | 4,423 | $31.38 |
| 2026-04-07 | MILLENNIUM MANAGEMENT LLC | 10% owner | Open market sale | 300 | $32.25 |
| 2026-04-07 | MILLENNIUM MANAGEMENT LLC | 10% owner | Open market sale | 1,108 | $33.38 |
| 2026-04-06 | MILLENNIUM MANAGEMENT LLC | 10% owner | Open market purchase | 1,104 | $31.02 |
| 2026-04-06 | MILLENNIUM MANAGEMENT LLC | 10% owner | Open market sale | 1,214 | $31.02 |
| 2026-04-06 | MILLENNIUM MANAGEMENT LLC | 10% owner | Open market sale | 45 | $31.96 |
| 2026-04-02 | MILLENNIUM MANAGEMENT LLC | 10% owner | Open market purchase | 26 | $33.47 |
| 2026-04-02 | MILLENNIUM MANAGEMENT LLC | 10% owner | Open market purchase | 1,276 | $34.75 |
| 2026-04-02 | MILLENNIUM MANAGEMENT LLC | 10% owner | Open market purchase | 701 | $35.55 |
| 2026-04-02 | MILLENNIUM MANAGEMENT LLC | 10% owner | Open market sale | 3,099 | $30.86 |
| 2026-04-02 | MILLENNIUM MANAGEMENT LLC | 10% owner | Open market sale | 1,265 | $31.75 |
| 2026-04-02 | MILLENNIUM MANAGEMENT LLC | 10% owner | Open market sale | 1,794 | $32.60 |
| 2026-04-02 | MILLENNIUM MANAGEMENT LLC | 10% owner | Open market sale | 374 | $33.35 |
| 2026-04-02 | MILLENNIUM MANAGEMENT LLC | 10% owner | Open market sale | 1,134 | $34.80 |
| 2026-04-01 | MILLENNIUM MANAGEMENT LLC | 10% owner | Open market purchase | 1,161 | $31.53 |
| 2026-04-01 | MILLENNIUM MANAGEMENT LLC | 10% owner | Open market purchase | 1,613 | $34.59 |
| 2026-04-01 | MILLENNIUM MANAGEMENT LLC | 10% owner | Open market purchase | 3,401 | $35.46 |
| 2026-04-01 | MILLENNIUM MANAGEMENT LLC | 10% owner | Open market sale | 1,104 | $31.52 |
| 2026-04-01 | MILLENNIUM MANAGEMENT LLC | 10% owner | Open market sale | 46 | $34.75 |
| 2026-03-31 | MILLENNIUM MANAGEMENT LLC | 10% owner | Open market purchase | 616 | $24.69 |
| 2026-03-31 | MILLENNIUM MANAGEMENT LLC | 10% owner | Open market purchase | 1,770 | $25.32 |
| 2026-03-31 | MILLENNIUM MANAGEMENT LLC | 10% owner | Open market purchase | 1,048 | $26.73 |
| 2026-03-31 | MILLENNIUM MANAGEMENT LLC | 10% owner | Open market purchase | 17 | $27.78 |
| 2026-03-31 | MILLENNIUM MANAGEMENT LLC | 10% owner | Open market purchase | 186 | $30.48 |
| 2026-03-31 | MILLENNIUM MANAGEMENT LLC | 10% owner | Open market purchase | 1,957 | $31.45 |
| 2026-03-31 | MILLENNIUM MANAGEMENT LLC | 10% owner | Open market purchase | 411 | $32.60 |
Showing the most recent 60 transactions.
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-21 22:34 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-09-17 | 8-K | 2026-09-11 | View on SEC.gov → |
| 2026-09-15 | 4 | 2026-09-11 | View on SEC.gov → |
| 2026-08-04 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-04 | 8-K | 2026-08-04 | View on SEC.gov → |
| 2026-07-23 | 8-K | 2026-07-21 | View on SEC.gov → |
| 2026-07-23 | 4 | 2026-07-21 | View on SEC.gov → |
| 2026-07-23 | 4 | 2026-07-21 | View on SEC.gov → |
| 2026-07-01 | 4 | 2026-06-29 | View on SEC.gov → |
| 2026-06-26 | 4 | 2026-06-24 | View on SEC.gov → |
| 2026-06-24 | 4 | 2026-06-22 | View on SEC.gov → |
| 2026-06-24 | 4 | 2026-06-22 | View on SEC.gov → |
| 2026-06-18 | 8-K | 2026-06-15 | View on SEC.gov → |
Recent news
Headlines about FTH (Faeth Therapeutics, Inc.). Links open the publisher — we don’t host full articles.
-
William Blair Expands Biotech Research as Veteran Analyst Alethia Young Initiates Coverage
Yahoo Finance · 2026-10-21 -
Citizens reiterates Faeth Therapeutics stock rating on cancer drug potential
Investing.com India · 2026-10-21 -
Faeth Therapeutics (FTH) to Present Preclinical Data on PIKTOR a
GuruFocus · 2026-10-19 -
Faeth to Present Preclinical Data on PIKTOR in HR+/HER2- Breast Cancer Models at ESMO 2026
Yahoo Finance · 2026-10-19 -
(FTH) Risk Channels and Responsive Allocation
Stock Traders Daily · 2026-10-18 -
FTH Upgraded by William Blair -- Rating Set to Outperform
GuruFocus · 2026-10-16 -
SNSE Stock Surges To 21-Month High – Everything To Know About Its Faeth Therapeutics Acquisition
Stocktwits · 2026-10-16 -
William Blair initiates Faeth Therapeutics stock with outperform rating
Investing.com · 2026-10-16
No headlines in this category right now — try “All”.